Abstract: An adaptive interactive preceptored teaching system for the remote education of a student provides lessons, obtains the student's profile, uses the profile to select one of the lessons to be sent to the student, and sends that lesson to the student. A method for remote care of a diabetic patient involves providing lessons, obtaining the patient's profile, using the profile to select a lesson to be sent to the patient, sending that lesson to the patient, offering the patient information reflecting the patient's health, and offering the patient's healthcare provider information regarding at least one of the patient's study of the lesson, the patient's health, and the patient's medical appointments. Communication can take place via the Internet, and can be effected in a secure manner.
Type:
Grant
Filed:
June 8, 2001
Date of Patent:
December 13, 2005
Assignees:
Noyo Nordisk Pharmaceuticals, Inc., Mayo Clinic
Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
Type:
Grant
Filed:
September 24, 2001
Date of Patent:
April 5, 2005
Inventors:
Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schäffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Søren Østergaard, Per Hertz Hansen
Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.
Type:
Grant
Filed:
November 1, 2002
Date of Patent:
February 22, 2005
Assignee:
Novo Nordisk Pharmaceuticals, Inc.
Inventors:
Brit Binow Sorensen, Lars Christian Petersen
Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.